A Revolution in R&D

More documents

Recommendations

Info

2 © The Boston Consulting Group, Inc. 2001. All rights reserved. For information or permission to reprint, please contact BCG at: E-mail: imc-info@bcg.com Fax: 617-973-1339, attention IMC/Permissions Mail: IMC/Permissions The Boston Consulting Group, Inc. Exchange Place Boston, MA 02109 USA Credits: Left cover photo by Bob Waterston, Washington University, St. Louis, Missouri. Used by permission. The photo shows a bird’s-eye view of one room in the DNA sequencing facility at the Whitehead Institute Center for Genome Research.
Table of Contents ABOUT THE AUTHORS 4 FOREWORD 5 EXECUTIVE SUMMARY 6 INTRODUCTION 9 CHAPTER 1: THE IMPACT OF GENOMICS 11 Preface 11 The Opportunities 12 The Challenges 18 A Final Word 21 CHAPTER 2: THE IMPACT OF GENETICS 24 Preface 24 Disease Genetics 27 Pharmacogenetics 33 A Final Word 39 CHAPTER 3: MANAGERIAL CHALLENGES 41 Preface: Looking Back and Looking Forward 41 Strategy—Searching for Genomic Competitive Advantage 41 Putting the Strategy into Operation 49 A Final Word 56 CONCLUSION 57 METHODOLOGY 59 3
Page 1 and 2: A Revolution in R&D HOW GENOMICS AN
Page 3: A Revolution in R&D HOW GENOMICS AN
Page 7 and 8: Foreword To meet growth targets, ph
Page 9 and 10: cogenetics). The productivity gains
Page 11: Introduction Throughout the pharmac
Page 14 and 15: 12 The Opportunities What is the im
Page 16 and 17: 14 and generally helping to optimiz
Page 18 and 19: 16 Cellomics are well positioned to
Page 20 and 21: 18 trials, if the company were able
Page 22 and 23: 20 almost to that of more familiar
Page 24 and 25: 22 UPSTART START-UPS—THE COMPETIT
Page 26 and 27: 24 Chapter 2: The Impact of Genetic
Page 28 and 29: 26 genetics-based form of pharmacog
Page 30 and 31: 28 DISEASE GENETICS—VARIOUS APPRO
Page 32 and 33: 30 Efficiency improvements in targe
Page 34 and 35: 32 duce targets high in quality but
Page 36 and 37: 34 would be excluded from the trial
Page 38 and 39: 36 Given these technological limita
Page 40 and 41: 38 Side-effect-based pharmacogeneti
Page 42 and 43: 40 moves, along with the relative s
Page 44 and 45: 42 POTENTIAL SAVINGS—FROM THEORET
Page 46 and 47: 44 ogy—to discover new drugs. Bro
Page 48 and 49: 46 INDUSTRY CHANGES The genomics la
Page 50 and 51: 48 Selecting Technologies According
Page 52 and 53: 50 tions, interfaces, and so on. Th
Page 54 and 55:
52 CASE STUDY: REDISCOVERING DISCOV
Page 56 and 57:
54 other—often literally—on col
Page 58 and 59:
56 The formidable operational and o
Page 61 and 62:
Methodology The many diverse studie
Page 63 and 64:
The Boston Consulting Group publish
show all

A Revolution in R&D

Create successful ePaper yourself

Delete template?

Save as template?